Intravitreal Injections of Sirolimus in the Treatment of Geographic Atrophy

Geographic Atrophy Clinical Trial

— Sirolimus  

Official title:

Multi-Center, Randomized, Single Masked Phase 2 Study of Intravitreal Injections of Sirolimus in the Treatment of Geographic Atrophy Associated With Age-Related Macular Degeneration

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT01675947
• Other study ID #: 3368-12056
• Status: Terminated
• Phase: Phase 2
• First received: August 28, 2012
• Last updated: December 8, 2015
• Start date: February 2012
• Est. completion date: February 2016

Study information

• Verified date: December 2015
• Source: National Eye Institute (NEI)
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

This study will seek to enroll 50 persons who have central or non-central geographic atrophy (GA) associated with age-related macular degeneration (AMD). GA in treated eye must be between 0.75 disk areas (DA) and 8 DA. Eligible participants will be randomly chosen to receive one of the following treatments in the study eye:

1. A 20 μL (440 μg) intravitreal (IVT) injection of sirolimus, or

2. A sham treatment (subconjunctival injection of lidocaine) Participants with two (2) eligible eyes will have one eye randomly assigned to receive intravitreal sirolimus and no sham in the fellow eye.

The first injection will begin at Day 0, which may occur on the date of screening/enrollment or up to two weeks following screening/enrollment visit, and every month thereafter. The visit schedule is as follows:

1. A clinical evaluation, including safety measures, will occur monthly.

2. Vision will be measured at the screening/enrollment visit and at 2, 3, 6, 9, 12, 18 and 24 months after the first injection has occurred.

3. Fundus autofluorescence will occur at screening/enrollment and at 2, 6, 12, 18 and 24 months after the first injection has occurred.

4. Fundus color photography and optical coherence tomography will occur at screening/enrollment and at 6, 12, 18 and 24 months after the first injection has occurred.

The primary goal is to evaluate whether the persons receiving the sirolimus injections show a slower worsening of geographic atrophy compared to the persons receiving the sham injections. A secondary goal is to evaluate the impact of sirolimus on vision compared to the sham.

NOTE: As of May 30, 2014, study injections were discontinued due to safety concerns. No further enrollments will occur and follow-up will continue on all active study participants on a quarterly basis. That is, on visits coinciding with 3 month intervals from date of enrollment.

Other known NCT identifiers

• NCT01664208

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 52
• Est. completion date: February 2016
• Est. primary completion date: June 2015
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 55 Years and older

Eligibility

Inclusion Criteria:

• Age 55 years of age or older. Prior participation in the Age-Related Eye Disease Study 2 (AREDS2) is not required.

• Participant must understand and sign the protocol's informed consent document.

• Participant must have central or non-central geographic atrophy (GA) in at least one eye. GA should be at least 0.75 disk areas (DA) in size but no more than 8 disk areas (DA); approximately 2.54 mm2 is 1 DA. GA is defined as one or more well-defined, usually more or less circular patches of partial or complete de-pigmentation of the retinal pigment epithelium (RPE), typically with exposure of underlying choroidal blood vessels. Even if much of the RPE appears to be preserved and large choroidal vessels are not visible, a round patch of RPE partial de-pigmentation may still be classified as early GA.

• Participant must have a steady fixation in the study eye in the foveal or parafoveal area and media clear enough for good quality photographs.

• Participant must have visual acuity between 20/25 and 20/200 in the study eye.

• Female participants must be post-menopausal.

• Male participants with female partners capable of conceiving children will be required to use contraception during the study and for four months after their last sirolimus injection.

Exclusion Criteria:

• Participant is in another investigational study other than AREDS2 and actively receiving study therapy for geographic atrophy or choroidal neovascularization (CNV).

• Participant is unable to comply with study procedures or follow-up visits.

• Participant has evidence of ocular disease other than AMD in either eye that may confound the outcome of the study (e.g., glaucoma, diabetic retinopathy with 10 or more hemorrhages or microaneurysms, uveitis, pseudovitelliform macular degeneration, moderate/severe myopia).

• Participant has received treatment for AMD, such as macular laser, photodynamic therapy (PDT) or anti-vascular endothelial growth factor (anti-VEGF) therapy injection. Or the participant received an IVT injection of any agent (e.g., triamcinolone) other than an anti-VEGF agent within the last four months prior to study enrollment. Vitamin supplementation for AMD is not considered an exclusionary criterion.

• Participant has had a vitrectomy.

• Participant is expected to need ocular surgery during the course of the trial.

• Participant has undergone lens removal in the last three months or Yttrium Aluminium Garnet (YAG) laser capsulotomy within the last month.

• Participant is on chemotherapy.

• Participant is on immunosuppressive medication or is immunosuppressed.

• Participant is on ocular or systemic medications known to be toxic to the lens, retina or optic nerve.

• Participant with a history of malignancy that would compromise the 2-year study survival.

• Participant with a history of ocular herpes simplex virus (HSV).

• A condition that, in the opinion of the investigator, would preclude participation in the study (e.g., unstable medical status including blood pressure and glycemic control).

• History of cancer (other than a non-melanoma skin cancer) diagnosed within the past five years that could be worsened by immunosuppression. (The risk of immunosuppression must be determined by an oncology consultation prior to enrollment.)

• Ocular or periocular inflammation or infection in either eye.

• Presence of active or inactive toxoplasmosis in the study eye.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Atrophy
• Geographic Atrophy

Intervention

Drug:
• Sirolimus
Immunosuppressive agent. Blocks the T-lymphocyte activation and smooth muscle and endothelial cell proliferation that occurs in response to antigenic and cytokine (interleukin IL-2, IL-4 and IL-15) stimulation through either Ca2+-dependent or Ca2+-independent pathways. Sirolimus arrests cell cycle progression by direct interaction with two intracellular proteins (immunophilin FK binding protein 12 (FKBP-12) and the mammalian target of rapamycin (mTOR), a multifunctional serine-threonine kinase). In cells, sirolimus binds to FKBP-12, and the resulting sirolimus-FKBP-12 complex then binds to and inhibits mTOR.
• Lidocaine
Lidocaine 2%

Locations

Country	Name	City	State
United States	Emory University	Atlanta	Georgia
United States	Elman Retina Group	Baltimore	Maryland
United States	Charlotte Eye Ear Nose & Throat Associates	Charlotte	North Carolina
United States	University of Illinois	Chicago	Illinois
United States	Texas Retina Associates	Dallas	Texas
United States	Vision Research Foundation	Grand Rapids	Michigan
United States	University of Florida HSC	Jacksonville	Florida
United States	Southeastern Retina Associates, P.C.	Knoxville	Tennessee
United States	Loma Linda University	Loma Linda	California
United States	University of Wisconsin	Madison	Wisconsin
United States	Scheie Eye Institute, University of Pennsylvania	Philadelphia	Pennsylvania
United States	University of California, Davis	Sacramento	California
United States	Palmetto Retina Center	West Columbia	South Carolina

Sponsors (3)

Lead Sponsor	Collaborator
National Eye Institute (NEI)	Santen Inc., The EMMES Corporation

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Number and severity of systemic and ocular toxicities, adverse events and infections		Monthly for 2 years	Yes
Primary	Rate of change in area of geographic atrophy		Every 6 months after enrollment for 2 years	No
Secondary	Change in best-corrected visual acuity		Every 6 months after enrollment for 2 years	No